CASE PRESENTATION
A 54-year-old Caucasian woman presented to a private physician with a twenty days history of fatigue, low grade fever, myalgias, arthralgias, Raynaud's phenomenon and dyspnoea on exertion. She was initially treated with 20mg of methylprednisolone as undifferentiated arthritis, and symptoms were improved. Attempts to taper down steroids led to relapse of manifestations. A new chest X-ray revealed increased lineal markings in lower lung fields ( Figure 1 ) and a chest CT scan showed linear markings, ground glass opacities and mild bronchiectasis ( Figure  2 arthritis, vasculitis, and myositis. An autoantibody panel with RF, anti-CCP, ANCA, and ANA was ordered. Legionella and Pneumococcal antigen urinary tests, serological tests for EBV, CMV, HIV, Parvo B19, mycoplasma and brucellosis, and Mantoux skin test were negative. Blood and urine cultures were sterile. The patient could not provide sputum for culture or immunofluorescence for Pneumocystis jirovecii. Beta D-glucan test for fungal infection was not available as a routine test in the microbiology laboratory of the hospital. The patient was empirically treated with broad spectrum antibiotics (intravenous piperacillin-tazobactam) without response. She progressively deteriorated with dyspnoea, tachypnoea, low pO2 (49 mmHg) requiring nasal oxygen supplementation, and rising CRP (6.3 mg/dl). Pulmonary embolism and acute heart failure were ruled out. Pneumocystis jirovecii pneumonia could not be excluded, and empirical treatment with co-trimoxazole (15 mg/kg/day) plus prednisone according to the treatment guidelines was initiated. Initially, the patient's clinical status and laboratory findings (CRP 0.7 mg/dl) were improved, but with prednisolone tapering, fever reappeared, and oxygen supplementation was again needed. Therefore, the possibility of an ILD associated with immune-mediated rheumatic diseases was very likely. Systemic sclerosis, systemic lupus erythematosus, Sjögren's syndrome, and vasculitis were unlikely, since there was no other feature of these diseases. Rheumatoid arthritis was still a possibility, but anti-synthetase syndrome became the most likely diagnosis. In our department, we perform an autoantibody profile for myositis-anti-synthetase syndrome by line immunoassay (Figure 3) . This multiplex test revealed very strong positivity for anti-Jo-1 (82 Arbitrary units, AU, cut off, 10) and anti-Ro52 antibodies (101 AU, cut off, 10). Antibodies against Mi-2 alpha, Mi-2 beta, TIF1γ, MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, SRP, PL-7, PL-12, EJ, and OJ) were all negative. Serum creatine phosphokinase (CPK) levels and electromyography were normal. Therefore, a diagnosis of anti-synthetase syndrome was made on the basis of ILD, fever, arthralgias, RP, and anti-Jo1 autoantibodies. High dose prednisolone was initiated along rituximab (1g on day 0 and day 15). The patient exhibited a quick improvement which continued during the following months with tapering of corticosteroids. At 1-year follow up, the patient is on 5 mg of prednisolone per day and rituximab (day 0-day 15) every six months. She is in good health, without the need of oxygen, and has started her work again. Chest x-rays and pulmonary function tests were normal.
DISCUSSION
Our case highlights the need for early recognition and treatment of aSS-ILD. Although aSS is associated with myositis, a patient may initially present with no myositis. 1 On the other hand, ILD is the most prevalent manifestation of aSS occurring in 86-95% of patients. 5, 6 ILD frequently dominates the clinical picture at presentation and may rapidly progress to pulmonary failure. In fact, aSS-ILD is more prevalent and severe rather than myositis-associated ILD. 4 ILD is more severe in anti-PL12/PL7 patients rather than anti-Jo-1 patients. 4 In fact, patients with anti-PL12/PL7 antibodies have predominant ILD, often without muscle involvement, whereas patients with anti-Jo-1 antibodies have more diffuse phenotype. 2, 5 The presence of anti-Ro52 antibody in patients with aSS may be associated with rapidly progressive ILD 6, 7 and cancer. 7 It should be noted that patients with ILD should also be tested for associated anti-signal recognition particle antibodies, including anti-MDA-5 (RNA helicase) and anti-Mi-2 (nuclear helicase). CT findings of aSS-ILD mostly include areas of ground glass opacities and reticulation, predominantly in lower lung lobes, and peribronchial lesions. Less frequently (~35%) there is organizing pneumonia with fibrosis. 8 Patients with aSS may also have myocarditis and pulmonary hypertension. 4 Myocarditis occurs in 34% of aSS patients and may be asymptomatic or present with acute/subacute heart failure. 9 No randomized control trials have been conducted in aSS, current therapy is off-label and based on case series and case reports, and includes corticosteroids along with an immunosuppressant, such as azathioprine, mycophenolate mofetil, calcineurin inhibitors (tacrolimus), rituximab and cyclophosphamide. 4 Rituximab seems to be a very effective option with marked improvement in FVC in patients with connective tissue disease and ILD, who have anti-Jo1 antibodies. 10 Significant improvement after treatment with rituximab is noted more frequently in anti-Jo1 antibody-positive compared to anti-Jo1 antibody-negative patients with inflammatory myopathies. In our case, an improvement in CT imaging features, as well as at FVC and DLCO tests, was observed over time. It must be noted that the greatest benefit was seen at the 3-year follow-up.
In conclusion, early recognition of aSS and investigation for major organ involvement is required for the optimal outcome of patients with this syndrome.
